Premium
Capillary electrophoresis of urinary prostate glycoproteins assists in the diagnosis of prostate cancer
Author(s) -
Vermassen Tijl,
Praet Charles,
Vanderschaeghe Dieter,
Maenhout Thomas,
Lumen Nicolaas,
Callewaert Nico,
Hoebeke Piet,
Van Belle Simon,
Rottey Sylvie,
Delanghe Joris
Publication year - 2014
Publication title -
electrophoresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.666
H-Index - 158
eISSN - 1522-2683
pISSN - 0173-0835
DOI - 10.1002/elps.201300332
Subject(s) - prostate cancer , prostate , fucosylation , prostate specific antigen , biomarker , glycan , urinary system , prostatitis , glycomics , pca3 , glycoprotein , glycosylation , medicine , urology , chemistry , cancer , biochemistry
Prostate marker assays are widely used for detection of prostate cancer (PCa) but are associated with considerable sensitivity and specificity problems. Therefore, we investigated prostatic protein glycosylation profiles as a potential biomarker. We determined the urinary asparagine‐linked glycan ( N ‐glycan) profile of prostatic proteins of healthy volunteers ( n = 25), patients with benign prostate hyperplasia (BPH; n = 62) and newly diagnosed PCa patients ( n = 42) using DNA‐sequencer‐assisted fluorophore‐assisted carbohydrate electrophoresis. Through squeezing of the prostate, a sufficient amount of prostatic proteins was obtained for direct structural analyses of N ‐glycan structures. N ‐glycans of PCa compared to BPH were characterized by a significant decrease in triantennary structures ( p = 0.047) and overall fucosylation ( p = 0.026). Prostate‐specific antigen (PSA) and the urinary glycoprofile marker showed comparable overall receiver operating characteristic curve analysis as well as in the diagnostic gray zone with serum PSA values between 4 and 10 μg/L. However, when combining PSA and the urinary glycoprofile marker, the latter gave an additive diagnostic value to serum PSA ( p ≤ 0.001). In conclusion, N ‐glycosylation profiling demonstrated differences between BPH and PCa. These changes could lead to the discovery of a new biomarker for PCa.